ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

Overview
Date Founded

1983

Headquarters

4464 Markham Street,Suite 3204,Victoria, BC V8Z 7X8

Type of Company

Public

Employees (Worldwide)

73

Industries

Biotechnology

Company Description

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

Executives & Employees

Chief Executive Officer, President & Director

Chief Financial Officer

Chief Scientific Officer

Chief Business Officer

General Manager, Canada

General Manager, Immunoprecise Antibodies Europe

Vice President-Marketing

Vice President of Corporate Services

Vice President of Client Relations

Vice President-Client Relations & Project Management

Board of Directors

Co-Founder at Monarch Labs, Inc.

President, Chief Executive Officer & Non-Independent Director at Brisio Innovations, Inc.

Chief Executive Officer at Lite Access Technologies, Inc.

Chief Business Officer at Open Monoclonal Technology, Inc.

Chief Executive Officer, President & Director at ImmunoPrecise Antibodies Ltd.

Professor-Emeritus at University of Victoria

Paths to ImmunoPrecise Antibodies Ltd.
Potential Connections via
Relationship Science
You
ImmunoPrecise Antibodies Ltd.
Recent Transactions
Details Hidden

ImmunoPrecise Antibodies Ltd. issued . USD Common Shares - Bought Deal

Details Hidden

ImmunoPrecise Antibodies Ltd. raised money in a private placement transaction

Details Hidden

ImmunoPrecise Antibodies Ltd. raised money in a private placement transaction

Transaction Advisors
Escrow Agent

Advised onImmunoPrecise Antibodies Ltd. issued . USD Common Shares - Bought Deal

Escrow Agent

Advised onImmunoPrecise Antibodies Ltd. issued . USD Common Shares - Bought Deal

Underwriter

Advised onImmunoPrecise Antibodies Ltd. issued . USD Common Shares - Bought Deal

Chief Operating Officer

Advised onImmunoPrecise Antibodies Ltd. issued . USD Common Shares - Bought Deal

Advisors & Consultants
Publicist

President, Chief Executive Officer & Non-Independent Director at Sentinel Resources Corp.

Publicist
Key Stats and Financials As of 2021
Market Capitalization
$111M
Total Enterprise Value
$131M
Earnings Per Share
$-0.36
EBITDAMargin
-17.9%
Enterprise Value / Sales
9.02x
TEVNet Income
-22.01x
Debt TEV
0.02x
Three Year Compounded Annual Growth Rate Of Revenue
48.76%
Revenue
$14.6M
Net Profit
$-5.97M
EBITDA
$-2.61M
Total Debt
$2.81M
Total Equity
$46.3M
Suppliers
Ligand Pharmaceuticals, Inc. Medical Support Services | La Jolla, CA

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by ImmunoPrecise Antibodies Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of ImmunoPrecise Antibodies Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and ImmunoPrecise Antibodies Ltd..